Sage Therapeutics, Inc.

NASDAQ
SAGE
Stock
Yield per half year: -8.84%
Dividend yield: 0%
Sector: Healthcare

Company Analysis Sage Therapeutics, Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (6.6 $) is less than fair price (8.13 $)
  • Current debt level 2.16% is below 100% and has decreased over 5 years from 3.44%.

Disadvantages

  • Dividends (0%) are below the sector average (0.527%).
  • The stock's return over the last year (-18.62%) is lower than the sector average (-0.4713%).
  • The company's current efficiency (ROE=-63.37%) is lower than the sector average (ROE=14.17%)

Similar companies

Incyte

Amarin

Alexion

ABIOMED

2. Share price and performance

2.1. Share price

2.3. Market efficiency

Sage Therapeutics, Inc. Healthcare Index
7 days -3.6% -5.5% 1.2%
90 days -4.6% 6.1% 21.7%
1 year -18.6% -0.5% 21.8%

SAGE vs Sector: Sage Therapeutics, Inc. has significantly underperformed the "Healthcare" sector by -18.15% over the past year.

SAGE vs Market: Sage Therapeutics, Inc. has significantly underperformed the market by -40.38% over the past year.

Stable price: SAGE is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: SAGE with weekly volatility of -0.3581% over the past year.

3. Summary of the report

3.1. General

P/E: 2.85
P/S: 8

3.2. Revenue

EPS -6.59
ROE -63.37%
ROA -56.06%
ROIC -26.63%
Ebitda margin -992.86%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (6.6 $) is lower than the fair price (8.13 $).

Price significantly below the fair price: The current price (6.6 $) is 23.2% lower than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (2.85) is lower than that of the sector as a whole (64.15).

P/E vs Market: The company's P/E (2.85) is lower than that of the market as a whole (90.03).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (0.7095) is lower than that of the sector as a whole (18.96).

P/BV vs Market: The company's P/BV (0.7095) is lower than that of the market as a whole (9.39).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (8) is lower than that of the sector as a whole (32.77).

P/S vs Market: The company's P/S indicator (8) is lower than that of the market as a whole (10.12).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-0.6368) is lower than that of the sector as a whole (274.79).

EV/Ebitda vs Market: The company's EV/Ebitda (-0.6368) is lower than that of the market as a whole (50.91).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Negative and has fallen by -33.22% over the last 5 years.

Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-33.22%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).

5.4. ROE

ROE vs Sector: The company's ROE (-63.37%) is lower than that of the sector as a whole (14.17%).

ROE vs Market: The company's ROE (-63.37%) is lower than that of the market as a whole (11.64%).

5.5. ROA

ROA vs Sector: The company's ROA (-56.06%) is lower than that of the sector as a whole (1.18%).

ROA vs Market: The company's ROA (-56.06%) is lower than that of the market as a whole (6.89%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (-26.63%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (-26.63%) is lower than that of the market as a whole (11.08%).

6. Finance

6.1. Assets and debt

Debt level: (2.16%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 3.44% to 2.16%.

Excess of debt: The debt is not covered by net income, percentage -2.95%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.527%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Sage Therapeutics, Inc.

9.3. Comments